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Background: Timely vaccination is important to protect children from common infectious diseases. We
assessed vaccination timeliness and vaccination coverage as well as coverage of vitamin A supplemen-
tation in a Ugandan setting.
Methods and ﬁndings: This study used vaccination information gathered during a cluster-randomized
trial promoting exclusive breastfeeding in Eastern Uganda between 2006 and 2008 (ClinicalTrials.gov no.
NCT00397150). Five visits were carried out from birth up to 2 years of age (median follow-up time 1.5
years), and 765 children were included in the analysis. We used Kaplan–Meier time-to-event analysis to
describe vaccination coverage and timeliness. Vaccination coverage at the end of follow-up was above
90% for all vaccines assessed individually that were part of the Expanded Program on Immunization
(EPI), except for the measles vaccine which had 80% coverage (95%CI 76–83). In total, 75% (95%CI 71–79)
had received all the recommended vaccines at the end of follow-up. Timely vaccination according to the
recommendations of theUgandan EPIwas less common, ranging from56% for themeasles vaccine (95%CI
54–57) to 89% for the Bacillus Calmette–Guérin (BCG) vaccine (95%CI 86–91). Only 18% of the children
received all vaccines within the recommended time ranges (95%CI 15–22). The children of mothers with
higher education had more timely vaccination. The coverage for vitamin A supplementation at end of
follow-up was 84% (95%CI 81–87).
Conclusions: Vaccination coverage was reasonably high, but often not timely. Many children were unpro-
tected for several months despite being vaccinated at the end of follow-up. There is a need for continued
ation
Some studies have shown that high vaccination coverage rates
for individual vaccines do not necessarily imply timely vaccina-
tion [3,6–9]. There may also be unspeciﬁc effects of vaccines that
can be inﬂuenced by the timing of the vaccinations, with poten-efforts to optimise vaccin
. Introduction
Timely vaccination is important to obtain adequate disease pro-
ection [1–3]. Delayed immunisation is a strong risk factor for
isease; in particular for pertussis and Haemophilus inﬂuenzae type
invasivedisease [1,2,4]. It hasbeenshownthat lateadministration
f the Bacillus Calmette–Guérin (BCG) vaccine is associated with
educed survival, while early administration improves survival [5].
Abbreviations: BCG, Bacillus Calmette–Guérin; CI, conﬁdence interval; DTP,
iphtheria, tetanus and pertussis; EPI, Expanded Programme on Immunization;
BV, hepatitis B; HiB, Haemophilus inﬂuenza type B; WHO, World Health Organi-
ation.
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Table 1
Coverage and timeliness of all the vaccines in the Ugandan EPI program. Coverage at the end of follow-up and the proportion receiving the vaccinations within the recom-
mended time periods (timely vaccination) are presented with 95% conﬁdence intervals. Similarly, untimely vaccination are categorised into vaccines given earlier or later
than recommended.
Coverage (at end of
follow-up)
Timely vaccination Given too early Given too late Not given (at end of
follow-up)
BCG vaccine 100% (99–100) 89% (86–91) 0% (0–0) 11% (9–13) 0% (0–1)
Polio 0 (1st oral polio vaccine) 94% (92–96) 67% (63–70) 0% (0–0) 27% (25–29) 6% (4–8)
Polio 1 (2nd oral polio vaccine) 99% (98–100) 70% (68–72) 1% (1–2) 27% (25–30) 1% (0–2)
DPT1+Hib+HBV (1st pentavalent vaccinea) 99% (98–100) 70% (68–73) 1% (1–2) 28% (25–30) 1% (0–2)
Polio 2 (3rd oral polio vaccine) 98% (96–99) 77% (74–78) 2% (1–3) 19% (17–21) 2% (1–4)
DPT2+Hib+HBV (2nd pentavalent vaccine) 97% (96–99) 76% (73–78) 2% (1–3) 20% (18–22) 3% (1–4)
Polio 3 (4th oral polio vaccine) 93% (90–94) 81% (79–83) 2% (1–3) 9% (9–10) 7% (6–10)
DPT3+Hib+HBV (3rd pentavalent vaccine) 93% (90–94) 83% (81–85) 1% (1–2) 9% (8–9) 7% (6–10)
Measles vaccine 80% (76–83) 56% (54–57) 12% (9–15) 12% (12–12) 20% (17–24)
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a The pentavalent vaccine protects against diphtheria, pertussis, tetanus, Haemop
ial negative consequences of delayed immunisation [10]. Thus, it
s important to take timeliness into account, as relying only on vac-
ination status can lead to a false assumption of disease protection.
Although some studies have evaluated timely vaccination of
ome selected vaccines, we are only aware of one study in the
nited States where timely vaccination for all nationally recom-
ended vaccines has been evaluated [9]. Only two studies have
ig. 1. Time when receiving vaccines presented with Kaplan–Meier plots (inverse and cu
ﬁfth vaccination visit), as well as vitamin A. The y-axis indicates the proportion having
ecommended age for vaccination (overlapping with red lines at birth for BCG and ﬁrst
ge. The horizontal dotted lines represent coverage at the end of follow-up. (2) The labels
f age is indicated as a scaling, but is also the upper recommended age for the measles va
s referred to the web version of the article.)inﬂuenzae type B and hepatitis B.
assessed timelyvaccination for someselectedvaccines inanAfrican
setting [8,11]. In this study, we assessed immunisation timeliness
and vaccination coverage in line with the Expanded Program on
Immunization (EPI) including vitamin A supplementation in Mbale
district, Eastern Uganda. To our knowledge, this is the ﬁrst study
outside the United States assessing timeliness for all the nationally
recommended vaccines for young children.
mulative) for the BCG- and polio0 vaccines (ﬁrst vaccination visit), measles vaccine
received the vaccines at each time point. (1) The blue vertical lines indicate the
polio vaccine), while the red lines indicate the outer ranges for the recommended
on the x-axis indicate the outer ranges for recommended vaccination age. One year
ccine. (For interpretation of the references to color in this ﬁgure legend, the reader
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Fig. 2. Time when receiving vaccines presented with Kaplan–Meier plots (inverse and cumulative) for the second, third and fourth vaccination visits where pentavalent
vaccines are given together with polio vaccines. The y-axis indicates the proportion having received the vaccines at each time point. (1) The blue vertical lines indi-
cate the recommended age for vaccination, while the red lines indicate the outer ranges for the recommended age. The horizontal dotted lines represent coverage at
the end of follow-up. (2) The labels on the x-axis indicate the outer ranges for recommended vaccination age. One year of age is indicated as a scaling, but is also the
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. Materials and methods
This studyusedvaccination informationcollectedbetween2006
nd 2008 during a community-based cluster-randomized con-
rolled trial promoting exclusive breastfeeding (ClinicalTrials.gov
o. NCT00397150) [12]. A total of 24 clusters accessible from roads
ithin a half an hour drive from Mbale Municipality in Mbale Dis-
rictwere chosen,with a population ofmore than 1 000 inhabitants
n each cluster. Six of the clusters were from urban areas and 18
f the clusters from rural areas. Each cluster had access to a water
ource, primary school andmarket or trading centre – independent
f other clusters. From these clusters, 886womenwere approached
ith consecutive sampling of women who were at least 7 months
or visibly) pregnant, intended to breastfeed and remain in the clus-
er for the coming year, and 863 recruited. Among these, 98 were
xcluded due to mother having moved or being lost-to-follow-up,
win delivery, death of the infant or mother before 3 weeks after
irth, or severe malformations, Fig. S1. Vaccination assessment
as done both for the intervention and control arms. Thus, 765
other–infant pairs remained in the analysis. The mother–infant
airs were scheduled to be interviewed at 3, 6, 12 and 24 weeks
fter birth,with anadditional follow-up interviewat around2years
f age. The median follow-up time was 1.5 years.s to color in this ﬁgure legend, the reader is referred to the web version of the
2.1. Study settings
In 2008, Mbale had a population of 403,100 [13]. The district is
predominantly rural with 59% home deliveries, and an antenatal
attendance of 95% [13]. The under-5-mortality rate was 137 per
1000 live births in 2004–2005, and the HIV-prevalence in Eastern
Uganda was 6.2% [13,14].
2.2. Data management
Data was collected through interviews by data collectors speak-
ing the local language Lumasaaba, and entered directly into
handheld computers with the program EpiHandy using an elec-
tronic questionnaire. Stata was used for analysis (version SE11.1,
Stata Corporation).
2.3. Vaccination timeliness and coverageThe EPI in Uganda recommends the following vaccines to be
given at speciﬁc ages (time ranges given in parentheses) [8,15]:
The ﬁrst vaccination is at birth where the BCG (birth to 8 weeks)
and oral polio (birth to 4 weeks) vaccines are given. The follow-
ing three vaccination visits includes the oral polio vaccine and a
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Fig. 3. Complete immunisation coverage and timeliness. The upper graph illustrates the proportion of the children receiving all the vaccines up to each speciﬁc vaccine. The
lower graph illustrates the proportion receiving all the respective vaccines within the recommended time ranges up to the speciﬁc time points. (1) Coverage: The line drops
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ime ranges, but does not get the given vaccine within the recommended range (e.g
ill add to the line drop at measles).
entavalent vaccinewhich protects against diphtheria, tetanus and
ertussis (DTP), H. inﬂuenzae type B (Hib) disease and hepatitis B
HBV). The ﬁrst dose is given at 6 weeks (4 weeks to 2 months),
hen again at 10 weeks (8 weeks to 4 months), and at 14 weeks
12 weeks to 6 months). The measles vaccine is given at 9 months
38 weeks to 12 months). Coverage was determined at the end
f follow-up. In Uganda, vitamin A supplementation is part of the
xpanded Program on Immunization [15], and was also assessed.
.4. Analysis
Vaccination timeliness was analysed with Kaplan–Meier time-
o-event analysis in line with Laubereau et al. [16]. Vaccination
ata and dates of birth were gathered from the children’s health
ards. Vaccination information based on maternal recall was also
ollected, but the data from the health cards are regarded to be
f better quality. Thus, the health card information has been used
or analysis when available. Most vaccinations were dated in the
ealth cards, but when vaccinations were registered without a
ate, we assumed that the age when the children were given the
peciﬁc vaccines was similar as for those with dated vaccinations.
he conﬁdence intervals were estimated with Greenwood’s point-
ise method. To investigate determinants of timely vaccination,
eused cluster adjustedCox regression analysis. As theCox regres-
ionmodel evaluated timelinesswhich has an accepted time range,
herewill be several ties (with the same vaccination time).Weused
he exact partial-likelihood method for handling ties to improve
odel robustness. The assumption of proportional hazards wasiven vaccine (e.g. if a child get all vaccines except the last pentavalent vaccine, the
e proportion that has got all the vaccines to that point within their recommended
hild get all vaccines within recommend time except the measles vaccine, the child
checked with Schoenfeld residuals, both graphically, with a sig-
niﬁcance test, and using a piecewise regression method. Tied cases
were handled with the exact partial-likelihood method. Rational
interactions were evaluated and were included in the model only
if they had signiﬁcant and meaningful effects. Log linearity was
checked with plotting of Martingale residuals for the complete
model vs. a model with one omitted variable. No variables were
strongly correlated with each other. We present a univariable as
well as a multivariable model, the latter using stepwise selection
with removal of covariates when p>0.1.
Socioeconomic wealth index was constructed with the use of
multiple correspondence analysis based on ownership of assets
as furniture and household characteristics including electricity,
a water source, roof material and toilet type. This method is
analogous to principal component analysis, and better suited for
categorical data [17]. The children’s families were grouped into
quintiles on the basis of socioeconomic rank.
2.5. Ethics
Ethical approval was granted by Makerere University Medi-
cal School Research, Ethics Committee and the Uganda National
Council for Science and Technology, and Regional Committees for
Medical and Health Research Ethics, Western Norway. Signed or
thumb-printed informed consent was obtained from each mother
prior to study participation. The consent procedure was approved
by the ethical committees.
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Table 2
Baseline characteristics for study participants presented with number (n) and percentages, and determinants for untimely vaccination (not receiving the vaccines within the
recommended time period) estimated with a Cox regression model with 95% conﬁdence intervals (cluster adjusted).
n (%)765 Hazard ratio for failure to timely
vaccination with 95% CI (unadjusted
modela)
Mother’s age
≤19 130 (17) 1
20–24 246 (33) 0.84 (0.63–1.12)
25–29 179 (24) 0.87 (0.65–1.18)
≥30 200 (26) 1.01 (0.74–1.36)
Marital status
Married or cohabiting 701 (92) 1
Single, widowed, separated or divorced 57 (8) 0.79 (0.49–1.26)
Gender of infant
Girl 375 (49) 1
Boy 387 (51) 0.99 (0.83–1.18)
Mother’s education
None 56 (7) 1
Primary education (1–6 years) 342 (45) 0.87 (0.67–1.12)
Secondary education (7–10 years) 284 (38) 0.76 (0.58–0.99)
Higher education (11 years or above) 74 (10) 0.53 (0.36–0.80)
Socio-economic wealth index
Poorest quintile 153 (20) 1
2nd quintile 183 (24) 1.04 (0.83–1.30)
3rd quintile 125 (16) 1.17 (0.91–1.51)
4th quintile 155 (20) 0.99 (0.77–1.28)
Least poor quintile 149 (19) 0.98 (0.78–1.22)
Living area
Rural 566 (74) 1
Urban 199 (26) 0.95 (0.73–1.22)
Place of delivery
Home 354 (48) 1
In facility (hospital, health clinic) 378 (52) 0.91 (0.74–1.11)
Health councelling
Normal 369 (48) 1
Additional peer-counselling 396 (52) 1.03 (0.90–1.17)
Number of siblings
None 173 (23) 1
1–2 232 (31) 1.02 (0.75–1.38)
3 or above 347 (46) 1.26 (0.95–1.67)
Mother’s body mass index (BMI)
<20 125 (19) 1
20–24.9 446 (68) 0.98 (0.81–1.18)
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≥30 10 (2)
a Only unadjusted model is presented as the only variable that was signiﬁcantly a
nd none were considered meaningful to include.
. Results
A health card was seen for 750 (98%) of the 765 participants.
f these, 732 (96%) were dated for at least one vaccine, Fig. S2. The
ajority haddatedhealth cards available formost of the interviews
ith the exception of the 2 years interview, when many cards had
een lost or were no longer readable due to wear and tear.
Vaccination coverage at the end of follow-up ranged from 80%
or the measles vaccine (95% conﬁdence interval 76–83) to 100%
or the BCG vaccine (95%CI 99–100), see Table 1 and Figs. 1 and 2,
ig. S3. The vaccination coverage rates for each vaccine at speciﬁc
ges (3 months, 6 months, 12 months and 18 months) and median
elays with inter-quartile ranges (IQR) are available in Table S1.
he proportion of infants that had received all the vaccineswas 75%
95%CI 71–79), see Fig. 3 which represents cumulative vaccination.
The coverage for vitamin A supplementation based on health
ard information was 84% (95%CI 81–87). Of these, 68% received
upplementation together with vaccines – in particular together
ith the BCG vaccine. Self-reported information on vitamin Aupplementation differed from health card information, with 94%
eporting that their children had been given vitamin A.
Timely vaccination ranged from 56% for the measles vaccine
95%CI 54–57) to 89% for the BCG vaccine (95%CI 86–91). Among
hose who were vaccinated late with the measles vaccine, the1.12 (0.88–1.43)
1.24 (0.72–2.15)
ted with vaccination timeliness was mother’s education. Interactions were checked
median age at vaccination was 64 weeks. This is equivalent to
a median delay of 24 weeks from the recommended timing (11
weeks delay from the end of the recommended range.) Only 18%
received all the vaccines within the recommended time ranges
(95%CI. 15–22).
3.1. Determinants of timely vaccination
The Cox regression model revealed a dose–response relation-
ship between mother’s education and timely vaccination, both in
the univariable analysis and the multivariable models, see Table 2.
This association was evident also when using years of schooling
as a continuous variable (hazard ratio 0.94 per year of education;
95%CI 0.91–0.97; p<0.001). Vaccination did not differ between the
intervention and control clusters of the intervention promoting
exclusive breastfeeding for 6 months through peer counselling.
4. DiscussionAlthough the coverage for the individual EPI vaccines was rea-
sonably high with the exception of the measles vaccine, timely
and age-appropriate vaccination was lower. About a quarter of
the vaccines were given outside the recommended time ranges.
Around 75% of the children received all the recommended vac-
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ines, but only 18% got all vaccineswithin their recommended time
anges. The coverage rates for the individual vaccines we report
ere slightly different from the national reported statistics from
ganda in 2008 [18,19]. According to these, Mbale District had a
overage rate of 85% for the third oral polio vaccine (compared to
ur estimate of 93%), which is higher than the national estimate of
9%. For measles, the reported number in Mbale was 105% (com-
ared to our estimate of 80%), with a national estimate of 77%. It is
ecessary to recognise that there is substantial variation across the
istricts, and that the nationally reported numbers may not accu-
ately reﬂect district-speciﬁc estimates, for example due to ‘cross
oundary immunisation’.
There ishardlyanydataonvaccination timeliness inUganda, but
ndings from studies having assessed timeliness elsewhere indi-
ate that timely vaccination is often far from optimal [3,6–9,11].
his strengthens the argument to monitor not only whether chil-
ren are vaccinated, but also when they receive the recommended
accines.
Despite gradual improvements in vaccination coverage and a
arge reduction inmeasles, pertussis and tetanusmortality, in 2008,
hese diseases were still responsible for about 4% of the child mor-
ality globally, and nearly 6% of around 190000 child deaths in
ganda [20]. These deaths are vaccine preventable, and diseases
uch as measles can potentially be eliminated with vaccination
21,22]. A coverage rate of measles vaccine exceeding 95% has been
ndicated as a necessary level when aiming for elimination [23,24].
his study population had measles vaccine coverage far below this
hreshold (80% coverage, and 56% received the measles vaccine
ithin the recommended time period). This leaves many children
usceptible todiseasesafter theirmaternal antibodiesdrop to levels
nsufﬁcient to protect them [1–3]. For the BCG vaccine, it has been
uggested that late administrationmay have an adverse impact [5].
here may also be indirect effects of timing of immunisation, but
arger studies are needed before conclusions about these potential
ffects can be made [10].
For the measles vaccine, it can be argued that early vaccination
hich was given to 12% in this study is an advantage, but this will
hen require re-immunisation as evoked immune responses are
eakened [23,25,26]. In addition, severely immunocompromised
hildrenmay develop activemeasles disease caused by themeasles
accination, which complicates immunisation assessment of some
IV-positive children [27].
Vitamin A was in this study given to nearly half of the babies
lready in theneonatal period. There is goodevidenceof abeneﬁcial
ffect on mortality from vitamin A supplementation between the
ge of 6 months and 5 years, but conﬂicting evidence when given
arly in infancy [28–32]. The information on vitamin A from this
tudy exempliﬁes how self-reported data can differ from recorded
ata, with an absolute discrepancy of 10%. As it may be difﬁcult
o remember whether a capsule was given to the child several
onths ago, we assume that the prospectively collected data from
he health cards is of better quality. The fact that many lost their
ealth cards, further complicates the decision for health personnel
n whether the children should give a vaccine or vitamin A dose
hen they come for a visit to the health clinic. These issues are
ikely to remain unsolved as long as only paper-based records are
sed as they are today.
It should be kept in mind that a complex system is required
o have a well functioning vaccination program [33]. Both con-
extual and individual factors are essential for utilization of health
ervices [34]. Identiﬁed characteristics of a well functioning vacci-
ation system include good availability of health services and short
aiting time, media promotion and campaigns [33]. Another key
actor is the distance to the clinics [35]. In Uganda, there are several
rogrammatic challenges that could partly explain the untimely
accinations. These include logistical challenges such as storage9 (2011) 3564–3570 3569
of sufﬁcient vaccine stocks at all times, maintaining a cold chain
system, and inadequate stafﬁng at health facilities.
A review of the effect of vaccination reminders concluded that
these were effective in improving vaccination rates – particularly
phone call reminders [36]. In settings where mobile phones are
becoming widespread, a strategy using either text messages or
phone call reminders could be a feasible option. There are already
some digital-based systems for immunisation in the pipeline tar-
geted also for low-income countries [37]. We think such a strategy
could give a better overview of the children’s vaccination status, as
well as opening opportunities for automated messages to remind
parents about vaccination visits. This could improve both timeli-
ness and coverage [36]. Connectingprogramswithdifferentdisease
preventive strategies can improve the quality as well as reducing
cost [38]. One suggestion has been to linkmeasles vaccinationwith
distribution bed-nets for malaria prevention.
Mother’s education was associated with timely vaccination.
Therewas an exposure-response trendwith timely vaccination and
education – the more education the better timeliness. It has also
been reported that maternal education has been associated with
better vaccine coverage [39]. The association between timely vac-
cination and higher education has also been suggested by a study
from the United States [9]. Other studies have also indicated that
poorer families often are more difﬁcult to reach with immunisa-
tion [40]. We did not ﬁnd any associations between socioeconomic
status and timely vaccination, and there were no tendencies to less
timely vaccinations among the poorest which is encouraging.
4.1. Limitations and strengths
The children who died during follow-up might have had dif-
ferent vaccination status compared to the surviving majority [41],
but mortality was low and therefore this is unlikely to have biased
the estimates substantially. As most of the clusters were close to
main roads, the clusters might have been easier accessible than
several other areas. Generalisability of the rates of timely vaccina-
tion and vaccination coverage is therefore limited to settings with
similar characteristics. The nationally reported statistics on vac-
cination can give some indications on how the ﬁndings relate to
other areas in Uganda, but these statistics are sub-optimal. The
much lower rates of timely vaccination than vaccination cover-
age has also been reported in several other settings, and are likely
to be applicable to a wider area. The timeliness of the few chil-
dren who had immunisation indicated as received but not dated
in the health card, could be different from the many where it was
dated. However, these children had similar baseline characteristics
(data not shown), and we therefore believe that this has not biased
the estimatesmarkedly. Contraindications for vaccinationwerenot
assessed [27], but this is applicable only for a few children. In some
cases, itmay be justiﬁed to postpone vaccination temporarilywhen
children aremoderately or severely ill [27]. Vaccination is then rec-
ommended to be given soon after recovery. Some children may
have been HIV-positive with severe immune suppression. Assess-
ment of whether and when measles vaccination for these children
should be given is more complicated [27]. Among those few who
had tested their children, none reported that their children were
HIV-positive (data not shown).
5. ConclusionsThis study shows that high immunisation coverage rates do not
necessarily imply age-appropriate vaccination status. Many chil-
dren were unprotected by vaccination for several months despite
being vaccinated at the end of follow-up. For the future, immuni-
sation monitoring should focus not only on whether children get
3 cine 2
i
i
A
t
i
y
c
p
2
c
h
D
e
e
n
p
A
t
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[570 L.T. Fadnes et al. / Vac
mmunised, but also when they do. Continued efforts are needed to
mprove vaccination timeliness.
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